First blood-stage malaria vaccine ‘a much-needed addition’ – analyst
The RH5.1/Matrix-M blood-stage vaccine could constitute a crucial secondary defence for communities at high risk of malaria infection, including those…
All articles by Eve Thomas
Eve Thomas
Eve Thomas is a reporter writing across a variety of sectors with a specific focus on thematic intelligence. She has a BA in English Literature from the University of Sheffield and an MSt in English from Oxford University.
-
-
APAC leading in Parkinson’s disease clinical trials
The Asia-Pacific (APAC) region is leading in the Parkinson’s disease clinical trial space globally with 44% of trials, according to…
-
CEPI funds safety project for vaccines in Africa
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced that it is providing up to $9.9m for a vaccine safety…
-
myTomorrows adds ISRCTN to clinical trial search
Netherlands-based global health platform myTomorrows has added the ISRCTN platform to its platform’s clinical trial search functionality. The platform now…
-
Generative AI has ‘potential to revolutionise clinical development’
Generative artificial intelligence (GenAI) has the potential to revolutionise clinical development – and certain key steps will help to unlock…
-
Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy
iTeos Therapeutics has announced that it has “deprioritised” inupadenant for the treatment of non-small cell lung cancer (NSCLC), following disappointing…
-
‘Major milestone’ for UK clinical trials as new framework laid in parliament
New legislation is being laid in the UK Parliament today (12 December) that will change the regulatory framework for clinical…
-
Cardiff Oncology announces positive colorectal data and $40m stock oversubscription
US-based clinical-stage biotechnology company Cardiff Oncology has announced positive initial data from its randomised Phase II clinical trial evaluating onvansertib…
-
UK desirability has turned a corner in clinical trials
The UK’s desirability as a clinical trial location is improving, reversing its previously downward trajectory, according to the Association of…
-
New strategy for Vivoryon as second failed Alzheimer’s trial shows kidney promise
Vivoryon Therapeutics has shared the results of its VIVA-MIND Phase IIa trial, considering varoglutamstat – an investigational oral glutaminyl cyclase…